Dr. Swanson is currently Executive Director of Clinical Development, Neurology Business Group, Neurodegenerative Diseases at Eisai, Inc, where he serves as the International Project Team Leader for a protofibril-selective monoclonal antibody (BAN2401) Program currently in development for Early AD and Preclinical AD.

Before joining Eisai, Dr. Swanson held clinical research positions in neurodegeneration at Merck and Schering Plough. Prior to his tenure in Clinical Development, Dr. Swanson was Senior Scientist and US Head of Neurochemistry, Target Discovery and Assessment, at Lundbeck, Inc, where he led a number of discovery programs and a lab devoted to discovery and preclinical research in psychiatric disease.

Dr. Swanson received his PhD from the Medical University of South Carolina in Physiology and Neuroscience, and his BS degree from the University of Wisconsin – Madison in Zoology with neurobiology emphasis.